Estimates of Future Diabetes Prevalence

Written by Bonnie Sanders Polin PhD

November is National Diabetes Month, so it's a good time to learn more about how to live with diabetes and support those who are researching how to keep us healthy. In the month of Thanksgiving, we'd like to thank those who on a daily basis work to find a cure. We wish them speed and good luck.

Patient Perceptions of Heart Attack Risk
We start with an article titled, "Perceptions of heart attack risk among individuals with diabetes" by Hermione C. Price, et al.

Medical professionals know that the risk of cardiovascular disease is much higher for people with diabetes than in those without the disease. These researchers from investigated patient perceptions of heart attack risk in people with diabetes in order to better understand their concept of risk factors.

They conducted three focus-groups using an open-ended question map and analyzed responses. Concern about having a heart attack varied widely. A commonly held view was that a 10-year risk of heart attack of 10% or more was significant, and that if they knew they fell into this group they would make the appropriate lifestyle changes. The researchers hope that physicians may use this information when discussing cardiovascular risk with diabetics and in providing risk reduction strategies.

Smoking and Diabetes
"Smoking and diabetes—the double health hazard," by Robert H. Fagard and Peter M. Nisson, reports that in patients with diabetes (as in non-diabetics), smoking is a significant factor for cardiovascular disease and mortality.

Estimates of Future Diabetes Prevalence
"Global estimates of the prevalence of diabetes for 2010 and 2030" by J.E. Shaw, et al estimates the number of people worldwide who will have diabetes in these two years.

Studies from 91 countries were used to calculate age- and sex-specific diabetes prevalences, which will help determine national diabetes estimates for all 216 countries for the years 2010 and 2030.

The world prevalence of diabetes among adults (aged 20-79 years) will be 6.4%, affecting 185 million adults in 2010 and will increase to 7.7% and 439 million adults in 2030.

Between 2010 and 2030, the estimates report a 69% increase in numbers of adults with diabetes in developing countries and a 20% increase in developed countries.

Hypoglycemia Costs and Risk
The final article is titled, "Direct costs associated with initiating NPH insulin verses Glargine in patients with type 2 diabetes: a retrospective study" by Lauren J. Lee, et al.

This study looked at total costs and risk of hypoglycemia in type 2 diabetic patients who started on NPH or Glargine in a real-world setting.

The study used claims data from a privately insured U.S. population with type 2 diabetes that were given either of the two insulins after a six month period free of insulin use.

There were 1698 patients treated with Glargine and 400 NPH-treated patients. Total diabetes-related costs were calculated for a 6-month pre-and post index periods and compared between 400 matched patient pair.

In the post-index 6-month period, Glargine patients incurred higher costs than NPH patients ($785 verses $632), but there were no significant differences in diabtetes-related medical or total costs.

Among people with hypoglycemia-related claims, the average hypoglycemia-related costs were $85 NPH and $202 for Glargine patients.